Invesco Ltd. cut its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 74.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,554,489 shares of the biotechnology company's stock after selling 4,475,485 shares during the quarter. Invesco Ltd. owned 0.23% of OPKO Health worth $2,285,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in OPKO Health during the fourth quarter worth $1,657,000. Essential Planning LLC. bought a new position in OPKO Health during the fourth quarter worth about $506,000. Barclays PLC boosted its holdings in OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock valued at $810,000 after purchasing an additional 329,870 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in shares of OPKO Health in the 4th quarter valued at approximately $255,000. Finally, Raymond James Financial Inc. acquired a new position in shares of OPKO Health in the 4th quarter worth approximately $221,000. 64.63% of the stock is currently owned by institutional investors.
OPKO Health Price Performance
NASDAQ OPK traded up $0.04 on Friday, hitting $1.39. 2,922,263 shares of the company were exchanged, compared to its average volume of 3,866,996. OPKO Health, Inc. has a 1-year low of $1.15 and a 1-year high of $2.04. The firm has a 50 day moving average of $1.61 and a two-hundred day moving average of $1.57. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company has a market cap of $930.10 million, a P/E ratio of -7.29 and a beta of 1.42.
OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The company had revenue of $149.90 million for the quarter, compared to the consensus estimate of $163.13 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. OPKO Health's revenue for the quarter was down 13.7% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. On average, equities analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.
Insider Buying and Selling at OPKO Health
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 200,000 shares of the stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $1.74 per share, for a total transaction of $348,000.00. Following the transaction, the chief executive officer now directly owns 213,501,448 shares in the company, valued at $371,492,519.52. This represents a 0.09 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In the last ninety days, insiders have bought 767,434 shares of company stock worth $1,238,312. Insiders own 49.69% of the company's stock.
Analysts Set New Price Targets
OPK has been the topic of a number of analyst reports. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research report on Friday, April 25th. They issued a "neutral" rating on the stock. Finally, Barrington Research reaffirmed an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a report on Thursday. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, OPKO Health currently has an average rating of "Moderate Buy" and a consensus target price of $2.75.
Get Our Latest Report on OPKO Health
About OPKO Health
(
Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
